Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, announced Jan. 10 that it has in-licensed rights for triheptanoin, a promising treatment for long-chain fatty acid oxidation disorders (FAOD), from Baylor Research Institute, the research arm of Baylor Health Care System.
“It is gratifying to see the fruits of everyone’s labor as this agreement moves forward,” said Dr. Raphael Schiffmann, director of BRI’s Institute of Metabolic Disease. “Staff have put a lot of time and effort into the study of triheptanoin and its use for fat oxidation and glycogen storage diseases among others.
“Triheptanoin has a potential benefit for these disorders and others with an underlying energy deficit, many of which do not have adequate therapy. We are confident that Ultragenyx will advance triheptanoin therapy for the benefit of these patients in the US and abroad.”
Contact:
Kristine Hughes
kristine.hughes@baylorhealth.edu
214.820.7556
About Baylor Scott & White Health
As the largest not-for-profit health system in the state of Texas, Baylor Scott & White promotes the health and well-being of every individual, family and community it serves. It is committed to making quality care more accessible, convenient and affordable through its integrated delivery network, which includes the Baylor Scott & White Health Plan, Baylor Scott & White Research Institute, the Baylor Scott & White Quality Alliance and its leading digital health platform – MyBSWHealth. Through 51 hospitals and more than 1,200 access points, including flagship academic medical centers in Dallas, Fort Worth and Temple, the system offers the full continuum of care, from primary to award-winning specialty care. Founded as a Christian ministry of healing more than a century ago, Baylor Scott & White today serves more than three million Texans. For more information, visit: BSWHealth.com